Chronic migraine is a disabling neurologic condition that affects 2% of the general
population. Patients with chronic migraine have headaches on at least 15 days a month …

There has been an increase in the number of chronic pain clinical trials in which the
treatments being evaluated did not differ significantly from placebo in the primary efficacy …

Background We tested erenumab, a fully human monoclonal antibody that inhibits the
calcitonin gene–related peptide receptor, for the prevention of episodic migraine. Methods …

Objectives: This is the second of a pair of studies designed to evaluate the efficacy and
safety of onabotulinumtoxinA (BOTOX®) for prophylaxis of headaches in adults with chronic …

(Headache 2010; 50: 921‐936) Objective.—To assess the efficacy, safety, and tolerability of
onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine …

Objectives: This is the first of a pair of studies designed to assess efficacy, safety and
tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic …

Objective To provide healthcare professionals with updated guidance in the use of novel
preventive and acute treatments for migraine in adults. Background The principles of …

Background Quality clinical trials form an essential part of the evidence base for the
treatment of headache disorders. In 1991, the International Headache Society Clinical Trials …

Background Switching between antibody classes might be a treatment option in migraine
patients who have not responded to one class of a CGRP-(receptor) monoclonal antibody …

Background Clinical trials have shown the safety and clinical superiority of erenumab
compared to placebo in chronic migraine (CM). The aim of this analysis is to evaluate the …